TFRC and acute myeloid leukemia: Although it is known that TFRC has a high expression level in cancerous cells in AML patients, whether the expression of TFRC in AML cells decreases after treatment with Ara-C has not been reported; the downregulated expression of TFRC will interfere the long-term effectiveness of targeted therapy based on TFRC.